United Therapeutics Corp.

United Therapeutics Corp. achieved a new 52-week high of USD 479.50 on October 29, 2025, reflecting strong performance in the pharmaceuticals sector. The company has seen a significant stock price increase over the past year, supported by solid fundamentals, positive cash flow, and financial stability.

United Therapeutics Corp. has recently adjusted its evaluation amid changing market conditions. The company's stock is priced at $421.04, reflecting a solid 20.23% return over the past year, outperforming the S&P 500. Its five-year performance shows a remarkable 242.92% return, highlighting its resilience in the pharmaceutical sector.

United Therapeutics Corp. has achieved a new 52-week high, reflecting its strong performance with a notable return over the past year. The company demonstrates operational efficiency with a solid return on equity and a low debt-to-equity ratio, alongside impressive operating cash flow and profit figures.

United Therapeutics Corp. has achieved a new 52-week high, reflecting its strong performance with a one-year return significantly exceeding the S&P 500. The company showcases robust operational efficiency, a solid balance sheet, and consistent positive results over the last eight quarters, highlighting its commitment to growth in the pharmaceuticals sector.

United Therapeutics Corp. has achieved a new 52-week high, reflecting its strong performance with a one-year return significantly above the S&P 500. The company showcases robust operational efficiency, a solid balance sheet, and positive financial results, indicating strong long-term fundamentals in the biotechnology sector.

United Therapeutics Corp. has experienced notable shifts in its technical indicators, with its stock price currently at 432.66. The company has shown strong performance, significantly outperforming the S&P 500 over various timeframes, including a remarkable 39.92% return in the past month and a 330.72% return over five years.

United Therapeutics Corp. has achieved a new 52-week high, reflecting its strong performance with a one-year return significantly above the S&P 500. The company, with a market cap of USD 28.35 billion, shows solid financial health, evidenced by a favorable return on equity and low debt-to-equity ratio.

United Therapeutics Corp. achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has shown impressive growth over the past year, with a solid return on equity and consistent positive results, highlighting its operational strength and market position.

United Therapeutics Corp. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock's daily moving averages are bullish, with a notable one-day performance increase. Over the past month, it has outperformed the S&P 500, demonstrating strong growth and a competitive market position.